This multicenter , open-label , comparator-controlled , phase III study randomly assigned healthy infants @-to-@ as follows : group @ received DTaP@-IPV-Hib-HepB , PCV@ , and RV@ at @ , @ , and @ months of age followed by DTaP@ , Hib-OMP , and PCV@ at @ months of age ; group @ received DTaP@-IPV/Hib , PCV@ , and RV@ at @ , @ , and @ months of age , with HepB at @ and @ months of age , followed by DTaP@ , Hib-TT , and PCV@ at @ months of age .